title: Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia.
abstract: Intense myelofibrosis is rarely associated with de novo acute myeloid leukaemia (AML) except in acute megakaryoblastic leukaemia (AML-M7) where there is diffuse marrow fibrosis as a consequence of proliferation of neoplastic myeloid cells. AML associated with significant myelofibrosis developing both de novo or secondary to primary (idiopathic) myelofibrosis is characterised by a fulminant course and extremely poor prognosis, primarily due to treatment-resistant disease. The prognostic value of degree of marrow fibrosis in de novo AML has been poorly investigated. We describe a case of extensive myelofibrosis associated with acute erythroblastic leukaemia (AML-M6) that responded to induction therapy of the leukaemia.
authors: Department of Medicine Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur. sfadilah@mail.hukm.ukm.my
authors: S-Abdul-Wahid
authors: SA
authors: Fadilah
authors: Raja-Sabudin
authors: RS
authors: Raja-Zahratul-Azma
authors: Chooi-Fun
authors: CF
authors: Leong
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D055728:Primary Myelofibrosis / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003561:Cytarabine; D003630:Daunorubicin